Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

- D ata show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model

Enlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis” in Cell Death & Disease, a Nature Research Journal

Nes-Ziona, Israel, June  18, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allowance for a patent application covering ALLOCETRATM, the company’s immunotherapy product candidate.  Upon issuance, the new patent will provide additional intellectual property protection around methods of using ALLOCETRATM and pharmaceutical compositions comprising the same. The company expects the new patent to issue in Japan during the third quarter of 2020.

Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy

Nes Ziona, Israel, June  01, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 8:00 AM ET.

Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

Nes Ziona, Israel, May  07, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of AllocetraTM (formerly referred to as off-the-shelf AllocetraTM) in COVID-19 patients has commenced.

Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients

Nes Ziona, Israel, April  13, 2020  (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) selected the Company’s planned COVID-19 and sepsis clinical programs to receive, in the aggregate, a non-dilutive grant of approximately $1.5 million for the period through the first quarter of 2021.  To date, Enlivex has received a total of approximately $4.31 million in grants from the IIA for its historical clinical trials and development.

Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials

– Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile and Extremely Difficult to Treat Population with Severe Sepsis –

Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

Nes-Ziona, March  09, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ALLOCETRATM, the company’s immunotherapy candidate. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in Israel.

Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment

Nes-Ziona, Israel, March  05, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused institutional investors, including Armistice Capital, of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant, for aggregate gross proceeds of $16.75 million.  

Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering

Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra TM  as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU

Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea

Nes-Ziona, Israel, March  02, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional investors, including Armistice Capital, for the purchase in a registered direct offering of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant.

Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering

Nes-Ziona, Israel, Feb.  26, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million.

Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering

Nes-Ziona, Israel, Feb.  24, 2020  (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of an aggregate of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share.

Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering

Shares of Israel-based Enlivex Therapeutics Ltd. ENLV, +4.90% rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to increase its manufacturing capacity of Allocetra, following the first confirmed case of COVID-19 in Israel.

Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms

Nes-Ziona, Israel, Feb.  24, 2020  (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity of AllocetraTM, following the first confirmed coronavirus (COVID-19) case in Israel, in preparation for potential requests for treatment of coronavirus (COVID-19) patients who are hospitalized with diagnosed organ dysfunctions or failures related to coronavirus.

Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure

Nes-Ziona, Israel, Feb.  20, 2020  (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a scientific presentation of two posters: (i) Allocetra-OTS: Early Apoptotic Cells for Immune Homeostasis in Human Stem Cell Transplantation (HSCT) and for the Prevention of Graft Versus Host Disease (GvHD)”, and (ii) “Apoptotic Cells Reprogram Resident Macrophages to Support Chimeric Antigen Receptor (CAR) T Cell Therapy Against Peritoneal Solid Tumor”, at the Transplantation & Cellular Therapy Meetings Conference of the ASTCT and CIBMTR (TCT), held on February 19-23, 2020, in Orlando, Florida.

Data On Enlivex’s Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida

News for Enlivex Therapeutics Ltd Stock (ENLV)